

New Medical Breakthrough Offers Hope for Degenerative Disc Disease with Mesenchymal Stromal Cell Therapy

Innovative Therapy Leads to Significant Pain Reduction and Improved Quality of Life for Patients

PHOENIX, AZ, UNITED STATES, November 11, 2023 /EINPresswire.com/ -- In the first half of 2022, a pioneering medical treatment was administered to 76 patients suffering from [degenerative disc disease](#), marking a significant milestone in pain management and rehabilitation. This press release delves into the remarkable outcomes observed in these patients, underscoring the potential of this innovative therapy.

Who Were the Patients? The treatment was given to a diverse group of patients, both men and women of different ages.

What Happened After the Treatment? A large number of these patients were closely followed up for a year. They were asked to fill out questionnaires about their condition at 3, 6, and 12 months after the treatment.

How Did the Treatment Help?

Pain Reduction: Patients reported a significant decrease in pain. On a scale from 0 (no pain) to 10 (extreme pain), the average pain score dropped by 2.3 points, which means their pain was reduced by about 37%.

Improvement in Daily Activities: The treatment also helped patients do their daily activities more easily. There was a 29% improvement in their ability to perform daily tasks without discomfort or limitations.

What's Next? The medical team plans to continue monitoring these patients and will provide more updates in the future.

Additional Details:

Patient Demographics and Follow-Up:

The treated cohort comprised diverse age groups and both sexes (Figure 1). Of these, 32 patients underwent a rigorous follow-up protocol. Impressively, high response rates were observed in the follow-up questionnaires - 91% at 3 months, 94% at 6 months, and 69% at 12 months post-therapy.

Pain Assessment Results:

Pain levels were meticulously assessed using the Visual Analogue Scale (VAS). The results were groundbreaking - patients reported an average pain reduction of 2.3 points (a 37% decrease) at 6 months, which remarkably persisted until 12 months post-therapy (Figure 2).

Disability Assessment Outcomes:

The Oswestry Disability Index (ODI) was employed to evaluate the impact of pain on daily activities. The findings were equally promising, with an average reduction of 9.8 points (29% decrease) in disability scores, sustained through 12 months post-therapy (Figure 3).

Future Plans:

The medical team remains committed to this path of innovation and patient care. Continuous monitoring of the patients is planned, with updates to be provided as more data becomes available.

This breakthrough in degenerative disc disease treatment not only offers new hope to patients suffering from chronic pain but also opens new avenues in the field of pain management and rehabilitation.

Bioxcellerator - Company Description:

"Bioxcellerator is a pioneering company at the forefront of [stem cell therapy](#) and regenerative medicine. With a commitment to innovation and excellence, Bioxcellerator specializes in groundbreaking advancements in the cellular therapy space. Our mission is to provide patients and the medical community with insight and opportunity to heal.

Bioxcellerator has established itself as a leader in stem cell therapy. Our team of experts and researchers is dedicated to pushing the boundaries of the regenerative medicine space to offer life-changing therapies and solutions that are both innovative and effective.

For more information about Bioxcellerator and our work, visit www.bioxcellerator.com.

Book a consultation today here <https://bit.ly/Bioxcellerator>

References

Navani A, Manchikanti L, Albers SL, Latchaw RE, Sanapati J, Kaye AD, Atluri S, Jordan S, Gupta A, Cedeno D, Vallejo A, Fellows B, Knezevic NN, Pappolla M, Diwan S, Trescot AM, Sooin A, Kaye AM, Aydin SM, Calodney AK, Candido KD, Bakshi S, Benyamin RM, Vallejo R, Watanabe A, Beall D, Stitik TP, Foye PM, Helander EM, Hirsch JA. Responsible, Safe, and Effective Use of Biologics in the Management of [Low Back Pain](#): American Society of Interventional Pain Physicians (ASIPP) Guidelines. Pain Physician. 2019 Jan;22(1S):S1-S74.

Leung, V. Y., Aladin, D. M., Lv, F., Tam, V., Sun, Y., Lau, R. Y., Hung, S. C., Ngan, A. H., Tang, B., Lim, C. T., Wu, E. X., Luk, K. D., Lu, W. W., Masuda, K., Chan, D., & Cheung, K. M. (2014). Mesenchymal

stem cells reduce intervertebral disc fibrosis and facilitate repair. Stem cells (Dayton, Ohio), 32(8), 2164–2177. Available from: <https://doi.org/10.1002/stem.1717>

Lykov, A. P., Bondarenko, N. A., Poveshchenko, O. V., Kim, I. I., Surovtseva, M. A., Sadykova, J. B., Semin, P. A., Zavjalov, E. L., Krivoschapkin, A. L., & Konenkov, V. I. (2020). Treatment of Intervertebral Disc Degeneration in Wistar Rats with Mesenchymal Stem Cells. Bulletin of experimental biology and medicine, 168(4), 578–582. Available from:

<https://doi.org/10.1007/s10517-020-04756-2>

Croft, A. S., Illien-Jünger, S., Grad, S., Guerrero, J., Wangler, S., & Gantenbein, B. (2021). The Application of Mesenchymal Stromal Cells and Their Homing Capabilities to Regenerate the Intervertebral Disc. International journal of molecular sciences, 22(7), 3519. Available from:

<https://doi.org/10.3390/ijms22073519>

Wei, A., Shen, B., Williams, L., & Diwan, A. (2014). Mesenchymal stem cells: potential application in intervertebral disc regeneration. Translational pediatrics, 3(2), 71–90. Available from:

<https://doi.org/10.3978/j.issn.2224-4336.2014.03.05>

Ekram, S., Khalid, S., Bashir, I., Salim, A., & Khan, I. (2021). Human umbilical cord-derived mesenchymal stem cells and their chondroprogenitor derivatives reduced pain and inflammation signaling and promote regeneration in a rat intervertebral disc degeneration model. Molecular and cellular biochemistry, 476(8), 3191–3205. Available from:

<https://doi.org/10.1007/s11010-021-04155-9>

Bioxcellerator

Bioxcellerator

+1 888-567-2469

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[Instagram](#)

[YouTube](#)

[TikTok](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/667753857>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.